Table 1

Model input parameters
Parameters Agomelatine Venlafaxine Fluoxetine Sertraline Escitalopram
Dose 25 mg 75 mg 20 mg 50 mg 20 mg
Percentage of patients receiving double dose 22.1% 11.8% 23.0% 24.5% 0.0%
Remission 0.323 [20-22] 0.323* 0.284 [22] 0.289 [21] 0.323*
Recurrence 20% [25] 20% [25] 20% [25] 20% [25] 20% [25]
Suicide risk 20.35 [26] 20.35 [26] 20.35 [26] 20.35 [26] 20.35 [26]
Discontinuation 0.117 [20-23] 0.216 [20] 0.171 [22] 0.189 [21] 0.144 [23]
Discontinuation symptoms 0.00 [27] 0.20 [27] 0.00 0.00 0.07
Relapse Survival function [28] Survival function [28] RR:0.513§ RR:0.633§ RR:0.531§
Constipation 0.027 [20-23] 0.042 [20] 0.011 [22] 0.006 [21] 0.006 [23]
Dyspepsia 0.020 [20-23] 0.024 [20] 0.008 [22] 0.013 [21] 0.025 [23]
Diarrhoea 0.040 [20-23] 0.018 [20] 0.027 [22] 0.057 [21] 0.069 [23]
Nausea 0.066 [20-23] 0.226 [20] 0.114 [22] 0.044 [21] 0.138 [23]
Somnolence 0.035 [20-23] 0.048 [20] 0.034 [22] 0.013 [21] 0.038 [23]
Headache 0.111 [20-23] 0.119 [20] 0.114 [22] 0.101 [21] 0.144 [23]
Sexual Dysfunction 0.005 [20-23] 0.018 [29] 0.004 [22] 0.019 [21] 0.013 [23]
Sleep Disorder 0.007 [20-23] 0.024 [20] 0.019 [22] 0.019 [21] 0.025 [23]

*assumed to be equal to agomelatine due to lack of relevant data.

§Meta-analysis vs. Placebo.

Maniadakis et al.

Maniadakis et al. BMC Health Services Research 2013 13:173   doi:10.1186/1472-6963-13-173

Open Data